Home › Compare › IRBS vs MRK

IRBS vs MRK: Dividend Comparison 2026

IRBS yields 3333333.33% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IRBS wins by $8.066963011092293e+41M in total portfolio value
10 years
IRBS
IRBS
● Live price
3333333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.066963011092293e+41M
Annual income
$806,648,697,106,848,200,000,000,000,000,000,000,000,000,000,000.00
Full IRBS calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — IRBS vs MRK

📍 IRBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIRBSMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IRBS + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IRBS pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IRBS
Annual income on $10K today (after 15% tax)
$283,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$685,651,392,540,820,900,000,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, IRBS beats the other by $685,651,392,540,820,900,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IRBS + MRK for your $10,000?

IRBS: 50%MRK: 50%
100% MRK50/50100% IRBS
Portfolio after 10yr
$4.033481505546146e+41M
Annual income
$403,324,348,553,424,100,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

IRBS
No analyst data
Altman Z
-999.7
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IRBS buys
0
MRK buys
0
No recent congressional trades found for IRBS or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIRBSMRK
Forward yield3333333.33% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$8.066963011092293e+41M$30.7K ✓
Annual income after 10y$806,648,697,106,848,200,000,000,000,000,000,000,000,000,000,000.00 ✓$950.29
Total dividends collected$8.066931866681733e+41M ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IRBS vs MRK ($10,000, DRIP)

YearIRBS PortfolioIRBS Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$333,344,033$333,333,333.33$11,192$351.54+$333.33M → IRBS
2$10,384,906,003,142$10,384,549,325,025.96$12,524$392.70+$10384905.99M → IRBS
3$302,363,748,270,118,850$302,352,636,420,695,500.00$14,015$438.65+$302363748270.10M → IRBS
4$8,227,619,721,265,916,000,000$8,227,296,192,055,268,000,000.00$15,682$489.96+$8227619721265916.00M → IRBS
5$209,235,859,949,820,440,000,000,000$209,227,056,396,718,700,000,000,000.00$17,547$547.23+$209235859949820444672.00M → IRBS
6$4,972,966,428,923,558,700,000,000,000,000$4,972,742,546,553,412,000,000,000,000,000.00$19,632$611.16+$4.972966428923559e+24M → IRBS
7$110,461,904,714,538,420,000,000,000,000,000,000$110,456,583,640,459,500,000,000,000,000,000,000.00$21,963$682.53+$1.1046190471453842e+29M → IRBS
8$2,293,122,282,540,014,600,000,000,000,000,000,000,000$2,293,004,088,301,970,000,000,000,000,000,000,000,000.00$24,571$762.18+$2.2931222825400146e+33M → IRBS
9$44,489,721,851,484,010,000,000,000,000,000,000,000,000,000$44,487,268,210,641,690,000,000,000,000,000,000,000,000,000.00$27,486$851.08+$4.448972185148401e+37M → IRBS
10$806,696,301,109,229,300,000,000,000,000,000,000,000,000,000,000$806,648,697,106,848,200,000,000,000,000,000,000,000,000,000,000.00$30,745$950.29+$8.066963011092293e+41M → IRBS

IRBS vs MRK: Complete Analysis 2026

IRBS — Stock

IR BioSciences Holdings, Inc. operates as a development stage biotechnology company in the United States. The company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia. It is involved in the development of Homspera, and its derivates Radilex and Viprovex, for human stem cell stimulation, immune system stimulation and anti-infective activity, vaccine adjuvancy, and wound healing. IR BioSciences Holdings, Inc. was founded in 1999 and is headquartered in Scottsdale, Arizona.

Full IRBS Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this IRBS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IRBS vs SCHDIRBS vs JEPIIRBS vs OIRBS vs KOIRBS vs MAINIRBS vs JNJIRBS vs ABBVIRBS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.